Introduction
norepinephrine, correlate with the poor prognosis of this syndrome [2] . Treatment of heart failure with b -selective 1 In chronic heart failure, neuroendocrine activation ocblockers, such as metoprolol [4] or bisoprolol [5] , have curs [1] , which is characterized by increased circulating been reported to improve symptoms and prognosis, in norepinephrine concentrations [2] and an increased release particular, in patients with dilated cardiomyopathy. Recentof norepinephrine from the heart [3] . The circulating ly, carvedilol, a nonselective b-blocker with vasodilatory norepinephrine concentrations, as well as the release of properties due to a-adrenoceptor antagonism, has been reported to improve prognosis in patients with ischemic and dilated cardiomyopathy [6] . The mechanisms by which rats were exposed to alternating 12 h dark and light cycles b-blockers exert these beneficial effects are not completely at 20-228C. Before sacrifice, blood pressures and heart elucidated. One potential key mechanism could be the rates were taken using the tailcuff method. Heart rate was restoration of b-adrenergic effects on myocardial force of also measured in vitro following sacrifice. Twelve rats contraction. The blunted positive inotropic effects of were included in each group. Animals were killed by a catecholamines are due to a downregulation [7] and blow on the head and were decapitated. Animals were bled uncoupling of b-adrenoceptors [8, 9] and an increase of from the carotid arteries. Serum was prepared from the inhibitory G-protein a-subunits [10, 11] , and are important sampled blood, frozen in liquid nitrogen and stored at mechanisms for contractile dysfunction in heart failure 2808C until the humoral measurements were performed. [12] . In endomyocardial biopsies from patients with heart
Hearts were quickly removed. Hearts of TG(mREN2)27 failure due to dilated cardiomyopathy, treatment with exhibited concentric hypertrophy, but no dilatation. No metoprolol for six months increased the number of bsigns of venous congestion were observed in any other adrenoceptors and restored the positive inotropic effect of organ. The hearts were retrogradely perfused according to the b-adrenoceptor agonist, dobutamine [13] . Interestingly, the Langendorff technique and the in vitro heart rate was treatment with carvedilol produced a similar increase in taken. After perfusion with Tyrode solution (in mmol / l: ejection fraction compared to metoprolol, but had no effect NaCl, 119.8; KCl, 5.4; CaCl , 1.8; MgCl , 1.05; 2 2 on the density of b-adrenergic receptors, as determined by NaH PO , 0.42; NaHCO , 22.6; Na EDTA, 0.05; ascorbic 2 4 3 2 right ventricular biopsies [14] . The use of myocardial acid, 0.28 and glucose, 5.0) for 5 min, the spontaneous biopsies for receptor ligand binding studies is hampered by heart rate was taken for 5 min. The preparations achieved a number of technical problems. Contamination with equilibrium heart rate within this time. Ten minutes after endocardial fibrous tissue can interfere with the exact sacrifice, left ventricles were immediately prepared, split determination of b-adrenoceptors in myocardial meminto three pieces from the basis to the apex and immedibranes. In addition, the amount of tissue is small. Thus, the ately frozen in liquid nitrogen. These techniques allowed alterations of the other signal transduction defects, like the us to study adenylyl cyclase activity, G-proteins and increase in inhibitory G-protein a-subunits and consecutive receptors in defined areas of the hearts. alterations of adenylyl cyclase activity, cannot be detected. In order to study the effects of carvedilol on the pathobiochemistry of b-adrenergic signalling, we investi-2.2. Adenylyl cyclase determinations gated the effects of carvedilol on myocardial neuropeptide Y concentrations, b-adrenoceptors, Gia and adenylyl Adenylyl cyclase activity was determined according to cyclase activity in a model of compensated cardiac hySalomon et al. [16] , with modifications as described pertrophy with pathobiochemical alterations similar to recently [17] . In brief, particulate washed membrane those observed in the failing human heart, namely a fractions (10 000 g sediment) were prepared from downregulation of b -adrenoceptors and an increase of homogenates of rat hearts (at approx. 48C). The activity of 1 Gia-proteins [15] . adenylyl cyclase was determined in a reaction mixture 32 containing 50 mmol / l P-a-ATP (approximately 0.3 mCi per 100 ml), 50 mmol / l triethanolamine-HCl, 5 mmol / l MgCl , 100 mmol / l EGTA, 1 mmol / l 3-isobutyl-1-2 methylxanthine, 5 mmol / l creatine phosphate, 0.4 mg / ml 2. Methods creatine kinase and 0.1 mmol / l cyclic adenosine monophosphate (cAMP) at pH 7.4 in a final volume of 100 ml.
Transgenic animals
The reaction was started by the addition of the membrane suspension. The mixture was preincubated for 5 min at Transgenic animals [TG(mREN2)27] [15] were housed 378C. The incubation time was 20 min at the same and treated in the animal laboratory of the Department of temperature. Reactions were stopped by the addition of Clinical Pharmacology, University of Groningen, Nether-500 ml of 120 mmol / l zinc acetate. Next, the zinc acetate lands. Sprague-Dawley (SD) control rats were the animals was neutralized by 600 ml Na CO (144 mmol / l). After 2 3
into which the transgene was originally introduced. Anicentrifugation for 5 min at 10 000 g, 0.8 ml of the mals were obtained from Møllegard (Denmark). Animals supernatant was applied to a neutral alumina column that were housed according to the guidelines of animal care of had been equilibrated with 0.1 mmol / l Tris-HCl, pH 7.5.
32
The Netherlands. Only male rats were used. The animals The effluent was collected and the P-labeled cAMP was were held on a standard laboratory animal diet (Hopedetermined by measuring the radioactivity in a liquid Farms, Woerden, Netherlands) and tap water ad libitum. scintillation spectrometer (LKB Wallac 1272 Clinigamma, Treatment was started at the age of seven weeks for 11
Freiburg, Germany Buchler, Braunschweig, Germany). min using a glass-glass homogenizer. The homogenate was spun at 484 g (rotor, Beckman JA 20) for 10 min. The 2.7. Miscellaneous supernatant was filtered through two layers of cheese cloth, diluted with an equal volume of ice-cold 1 mol / l KCl and Protein concentrations were determined according to stored on ice for 10 min. This suspension was centrifuged Lowry et al. [18] using bovine serum albumin as the at 100 000 g for 30 min. For radioligand binding experistandard. SDS-PAGE was performed as described by ments, the pellet was resuspended in 50 volumes of Laemmli [19] . incubation buffer (50 mmol / l Tris-HCl, 10 mmol / l MgCl , pH 7.4) and homogenized for 1 min with a 2.8. Materials 2 glass-glass homogenizer. This suspension was recentrifuged at 100 000 g for 30 min. The final pellet was Forskolin was donated by Hoechst, Frankfurt, Germany. resuspended in incubation buffer (50 volumes) and was Guanosine-59-triphosphate (GTP), guanylylimidodiphosstored at 2808C. All preparation steps were performed on phate [Gpp(NH)p], adenosine-59-triphosphate (ATP), ice in a cool room at 48C. Centrifugation steps were also creatine phosphate and creatine kinase were purchased performed at 48C. Previous experiments in our laboratory from Boehringer-Mannheim (Mannheim, Germany) and have shown that storage for up to three years at 270-808C isobutylmethylxanthine (IBMX) was from EGA-Chemie 125 does not alter adenylyl cyclase activity and G-protein or (Steinheim, Germany). The ligand I-labeled cyanopinreceptor content.
dolol (Cyp) was from Amersham-Buchler (Braunschweig, Germany). Dithiothreitol was from Serva (Heidelberg, 2.4. Radioligand binding studies Germany). Pertussis toxin was from List Biological Laboratories (Campbell, USA). All other compounds used The assays were performed in a total volume of 250 ml were of analytical grade or the best grade commercially incubation buffer (for composition, see above). The incuavailable. Only deionized and double distilled water was bation was carried out at 258C for 120 min. These used throughout. Carvedilol was provided by Boehringerconditions allowed complete equilibration of the receptors Mannheim (Mannheim, Germany). with the radioligand. The reaction was terminated by rapid vacuum filtration through Whatman GF / C filters, and 2.9. Statistics filters were immediately washed three times with 6 ml each of ice-cold incubation buffer. All experiments were
The data shown are means6SEM. Statistical signifiperformed in triplicate. Myocardial b-adrenoceptors were cance was estimated with analysis of variance according to 125 studied using I-labeled cyanopindolol, as previously Wallenstein et al. [20] . A Bonferroni correction was used described [11, 15] 
Pertussis toxin-induced P-ADP-ribosylation
32 P-ADP-ribosylation of Gia by pertussis toxin was 3. Results performed for 12 h at 48C in a volume of 50 ml containing 100 mmol / l Tris-HCl, pH 8.0 at 208C, 25 mmol / l 3.1. Blood pressure, heart rate and heart weight dithiothreitol, 2 mmol / l ATP, 1 mmol / l GTP, 50 nmol / l 32 P-labeled NAD (800 Ci / mmol) and 20 mg / ml pertussis As summarized in Table 1 , systolic blood pressure and toxin that had been activated by incubation with 50 mmol / heart rate were significantly higher in TG(mREN2)27 l dithiothreitol for 1 h at 208C prior to the labeling compared to SD. Treatment with carvedilol significantly reaction, as described earlier [17] . Samples were subjected reduced the heart rate and blood pressure. Consistently, to sodium dodecyl sulfate polyacrylamide gel electrorate pressure product was increased in TG(mREN2)27 phoresis (SDS-PAGE) [10% (w / v) acrylamide, 16 cm compared to SD but was significantly reduced following treatment with carvedilol (Table 1 ). Fig. 1A shows the membranes. As shown in Fig. 1C , the number of bdifference in heart rate in vivo and in vitro. The difference adrenergic receptors was significantly reduced in hearts in heart rate was more pronounced in TG(mREN2)27 than from TG(mREN2)27 compared to untreated controls. In in SD, as an indicator of increased catecholamine drive in carvedilol-treated TG(mREN2)27, the receptor density was vivo in transgenic rats. In carvedilol-treated rats, this even lower than in untreated TG(mREN2)27. difference was reduced to control values. Thus, excess stimulation was completely blocked by carvedilol. The 3.4. Inhibitory G-protein a-subunits heart rate in vitro, as determined in Langendorff isolated heart preparations, did not differ (Table 1 ). In contrast, the Besides the downregulation of b-adrenergic receptors, increase in relative left ventricular weights in hypertensive the increase of inhibitory G-protein a-subunits has been TG(mREN2)27 compared to SD was not significantly identified as one cause of adrenergic subsensitivity in reduced by carvedilol ( Table 1) . The relative right vencardiac failure and hypertrophy. As shown in original tricular weights did not differ (Table 1) . Taken together, autoradiographs (Fig. 2, upper panel) , hearts of carvedilol treatment reduced the elevated heart rate in vivo TG(mREN2)27 exhibited an increase in pertussis toxinand reduced blood pressure, but had no significant effect 32 catalyzed incorporation of P-ADP-ribose into a 40-kDa on left ventricular hypertrophy in TG(mREN2)27. Lung substrate, presumably Gia. Treatment with carvedilol did water was not significantly changed in TG(mREN2) 27 not reduce pertussis toxin substrates in TG(mREN2)27 (3.060.13 mg / g, n511) compared to control rats compared to SD (Fig. 2) . (2.6260.07 mg / g, n514, n.s.). However, 1dp / dt was similar in TG(mREN2)27 compared to SD (66856379 mmHg / s, n58 vs. 60006212 mmHg / s, n59, n.s.). In 3.5. Adenylyl cyclase activity contrast, the rate of relaxation (2dp / dt) was significantly reduced in TG(mREN2)27 compared to SD (57716371 vs. Fig. 3 summarizes the effect of carvedilol treatment on 71596454 mmHg / s, n59, p,0.05).
adenylyl cyclase activity. Basal adenylyl cyclase was reduced in TG(mREN2)27 compared to SD (Fig. 3A) .
Myocardial neuropeptide Y concentrations
Also, the effects of isoprenaline, Gpp(NH)p or forskolin on adenylyl cyclase activity were depressed (Fig. 3B-D) . Neuropeptide Y is costored and coreleased with norepiCarvedilol treatment did not significantly increase adenylyl nephrine from sympathetic nerve terminals [21] . During cyclase activity compared to values in TG(mREN2)27 chronic stimulation, myocardial sympathetic nerve termicontrols. In order to assess whether or not depressed nals become depleted of neuropeptide Y. Fig. 1B shows forskolin-stimulated enzyme activity is due to an alteration that myocardial neuropeptide Y concentrations are reduced of the catalyst activity of adenylyl cyclase, experiments by about 47% in TG(mREN2)27 compared to control rats.
were performed in the presence of 5 mmol / l MnCl and in 2
The reduction of blood pressure by carvedilol did not alter the absence of MgCl . Under this condition, the adenylyl 2 myocardial concentrations of neuropeptide Y. cyclase is uncoupled from the influence of G-proteins [22] .
In the presence of manganate ions, there was no difference 3.3. b-Adrenergic receptors between SD and TG(mREN2)27, independent of whether rats were treated with carvedilol or not (not shown). Thus, The density of myocardial b-adrenergic receptors was the catalyst activity is not altered in TG(mREN2)27 and is determined by radioligand experiments in myocardial not affected by carvedilol treatment. 
Interaction of carvedilol with b-adrenergic receptors
One would expect that b-blocker treatment restores desensitized adenylyl cyclase activity. Since this is not the case, this finding points towards an atypical interaction of carvedilol with b-adrenergic receptors. In order to investi- (Fig. 4) . binding in the absence of Gpp(NH)p. In the presence of antagonist carvedilol. Carvedilol reduced rate-pressurethe guanine nucleotide, the curve shifts to the right and product and significantly decreased, but did not normalize, becomes monophasic, with a Hill coefficient close to one blood pressure. Left ventricular weights were not sig- (Table 2 ). In contrast, binding of the b-adrenoceptor nificantly reduced. In hypertensive rats, there was a antagonist metoprolol was not affected by Gpp(NH)p ( 4C. Competition by carvedilol for I-Cyp-binding was insensitive to carvedilol. As reported before, adenylyl also compatible with binding to two sites with high and cyclase activity was desensitized by an increase in inhiblow affinity. As with the agonist isoprenaline, carvedilol itory G-protein a-subunits and a downregulation of bcompetition curves were shifted to the right by Gpp(NH)p adrenoceptors in TG(mREN2)27 [15] . Carvedilol treatment and became monophasic. Differences in the distribution of did not resensitize adenylyl cyclase, but even decreased high and low affinity states between the receptor subtypes myocardial b-adrenergic receptor numbers. Treatment had were not determined, due to the scatter of the binding no effect on the amount of myocardial Gia. In radioligand curves, which allows only a qualitative comparison. Taken binding experiments, carvedilol behaved in a manner together, binding characteristics of the b-blocker antagosimilar to that of the agonist isoprenaline, but different nist carvedilol are atypical and resemble in some aspects from that of metoprolol, because it exhibited guaninethose of b-adrenoceptor agonists.
nucleotide-modifiable binding.
b-Adrenergic signal transduction in cardiac failure

Discussion
and hypertrophy b-Adrenergic neuroeffector transmission was characterThe failing human heart exhibits a desensitization of ized in transgenic rats with compensated cardiac hyperadenylyl cyclase with a consecutive blunted response to trophy following treatment with the b-adrenergic receptor cAMP-elevating positive inotropic agents [7] [8] [9] 23 ]. The syndrome [26] . According to the Framingham study, arterial hypertension producing chronic pressure overload on the heart is one prominent cause of heart failure [27] . In several models of pressure overload, including the hearts of patients with hypertensive heart disease, a desensitization of b-adrenergic effects by variable alterations of b-adrenergic receptors and G-proteins has been identified [28] . These findings have attracted the idea that b-adrenergic desensitization could be a mechanism that occurs before the manifestation of heart failure in compensated hypertrophy due to pressure overload and could contribute to the progression from compensated hypertrophy to overt heart failure.
It is important to note that all animal models have limitations for extrapolation of the data generated to the situation in chronic heart failure in humans. In particular, strong differences occur in b-adrenergic signal transduction. In models with renal failure, corticosteroid hypertension and Goldblatt-hypertension, adenylyl cyclase is reduced, due to postreceptor events rather than to a downregulation of b-adrenergic receptors [28] . Among the various models, transgenic rats harbouring the mouse renin 2d gene exhibit alterations of b-adrenergic signal transduction in the heart, which are similar to those observed in human cardiomyopathic tissue [28] . These rats develop fulminant hypertension with myocardial hypertrophy [29] . Myocardial norepinephrine and neuropeptide Y concentrations are depleted, whereas plasma concentrations of neuropeptide Y and norepinephrine are increased [15] . Adenylyl cyclase is desensitized, due to a reduction in b -adrenoceptors by 50% and an increase of inhibitory 1 G-proteins by 40%. In addition, the velocities of contraction and relaxation are reduced in isolated cardiac preparations. This is due to a depressed gene and protein 21 expression of the sarcoplasmic reticulum Ca -ATPase, and of phospholamban [30] . The biochemical alterations contributing to contractile alterations clearly correlate to those observed in human heart failure [31] . Nevertheless, since, in contrast to the situation in human heart, failure of systolic function is not affected to these extents, the models of compensated cardiac hypertrophy are mostly, if not exclusively, suitable for biochemical characterization rather than for determining the effects on contractile performance. This transgenic model has been chosen to 
Effects of b-blockers
underlying cellular mechanisms are a downregulation of A variety of studies have shown that b-blocker treatb -adrenergic receptors [8, 9] , an increase of the b-adrenment improved ejection fraction, submaximal exercise 1 ergic receptor kinase (b-ARK) [24] and of Gia-proteins in tolerance and left ventricular filling pressures [12] [13] [14] . membranes from myopathic hearts [10, 11, 23, 25] . SympaMetoprolol treatment has been reported to reduce the need thetic activation has been suggested to be the crucial for cardiac transplantation in dilated cardiomyopathy [4] . mechanism for inducing these cellular alterations, and is Bisoprolol improved the prognosis in patients with dilated suggested to be linked to the poor prognosis of this cardiomyopathy [5] . Recently, a reduction in mortality by about 65% has been reported for both ischemic and dilated control rats. Thus, b-blockade by carvedilol was sufficient. cardiomyopathy in the US Carvedilol Heart Failure Trials
In TG(mREN2)27, the number of b-adrenergic receptors [6] . The mechanisms by which b-blocker treatment was significantly reduced. Carvedilol did not restore, but favourably act are poorly understood. One candidate even reduced, b-adrenergic receptor numbers. In the same mechanism is the restoration of b-adrenergic receptormodel, antihypertensive treatment with captopril and the effector coupling, with improvement of cardiac perform-AT -receptor antagonist, Bay 10-6734, restored adenylyl 1 ance. Indeed, metoprolol treatment for six months incyclase [35] . This effect has been attributed to an increase creased ejection fraction and increased the number of in the number of b-adrenergic receptors, normalization of b-adrenergic receptors in right ventricular biopsies [13] .
Gia-proteins and was accompanied by a partial restitution Recently, Gilbert et al. [14] reported similar increases of of neuropeptide Y concentrations in the heart. In the ejection fraction by treatment with metoprolol or carpresent study, carvedilol had neither an effect on myocarvedilol. Interestingly, the number of b-adrenergic receptors dial neuropeptide Y-concentrations nor did it increase the increased after metoprolol, but not after carvedilol, treatdensity of b-adrenergic receptors. The reduction of bment. This finding pointed towards an atypical effect of adrenoceptor density is even different from previous carvedilol on myocardial b-adrenergic receptors.
observations in humans. Carvedilol did not increase the The measurement of b-adrenergic receptors in endonumber of b-adrenergic receptors in patients with heart myocardial biopsies is hampered by several biological and failure [14] , whereas the b -adrenoceptor antagonist meto-1 technical difficulties, due to the small amount of sample prolol significantly upregulated b-adrenoceptor numbers in and due to contamination by large amounts of fibrous myocardial biopsies [13, 14] . Both studies, at least, did not tissue. Therefore, we set out to determine the effects of show an increase of b-adrenoceptors as one would expect. carvedilol in a model with similar pathobiochemical
The reduction in rats but not in humans could be explained alterations as in the failing human heart. by the relatively higher dose producing a larger receptor occupation, which cannot be obtained in humans. Interest-4.3. Effects of carvedilol on b-adrenergic signal ingly, carvedilol reduced the transcardiac gradient of transduction released norepinephrine, whereas metoprolol had no significant effect on norepinephrine release in the failing Carvedilol is a b-adrenergic receptor antagonist with a human hearts [14] . Therefore, the lack of effects of low selectivity to b -adrenoceptors, which, in vivo, is of carvedilol on b-adrenergic receptor densities cannot be 1 no, or only minor, importance [32] . In addition, it produces explained by a failure of the compound to reduce myocarvasodilatation by a1-adrenoceptor antagonism and exhibits dial norepinephrine release. Altogether, the data point antioxidative [33] and antiproliferative effects in smooth towards an atypical effect of carvedilol on b-adrenergic muscle cells [34] . In TG(mREN2)27, carvedilol reduced receptors, which, unlike with other b-blockers, prevents the rate pressure product to values similar to those in upregulation of b-adrenergic receptors [14] or can even control rats. In addition, the differences between heart rate downregulate the b-adrenoceptors (these experiments). As determined in vivo and in vitro was reduced in carvedilolshown in experiments on myocardial membranes, cartreated TG(mREN2)27, giving values similar to those in vedilol binds to b-adrenergic receptors with two affinity 2d states. The high affinity state of binding sites can be mouse renin, ren , gene. The consequence is a fulminant transformed to a low affinity status by the application of hypertension and a strong sympathetic activation. The the nonhydrolysable guanine nucleotide, Gpp(NH)p. This pathobiochemical alterations are a reduction of b -adren- 1 indicates that the binding properties of carvedilol are ergic receptors and an increase of Gia-proteins. Compared similar to those of the agonist isoprenaline [36] , although with other models of experimental or hereditary left carvedilol has no intrinsic sympathomimetic activity. Simiventricular pressure overload, TG(mREN2)27 have the lar effects have been reported in human myocardial greatest similarities concerning their rigorously studied membranes [35] . These peculiarities of the compound b-adrenergic signal transduction defects to those observed could explain why b-adrenoceptor numbers do not recover, in the failing human heart [15, 28, 29] . Nevertheless, we but are even more downregulated, in TG(mREN2) 27 would like to point out that this is not a model for heart following carvedilol treatment. In support of this notion failure. It just has close pathobiochemical similarities to are data on chicken cardiomyocytes, in which carvedilol this condition. Thus, it seems worthwhile to study pharmaalso downregulated b-adrenergic receptors [32] .
cological interventions that have the potential to delay or Besides a downregulation of b-adrenergic receptors, an prevent progression in such a model. The investigation can increase of Gia-proteins has been described in the failing only provide insights into the pathobiochemistry and the heart [10, 11] and in left ventricular myocardium of effects of carvedilol thereon. Since TG(mREN2)27 exhibit TG(mREN2)27 [15] . This pathobiochemical change is a more or less preserved systolic function, functional most likely induced by chronic b-adrenoceptor stimulation determination following pharmacological treatment seems of the heart [37] . The increase in Gia-related pertussis to be of no value. toxin substrates induced by norepinephrine was due to an increase in the transcription rate of the Gia2-gene, as determined by nuclear run-on assays [38] and was sensi-5. Conclusions tive to the b-adrenoceptor antagonists [37, 38] . One would expect that b-adrenoceptor blockade or treatment with In the used model of pressure overload and sympathetic agents that reduce sympathetic activation would normalize activation, adenylyl cyclase is desensitized, due to a the elevated levels of Gia-proteins. In myocardial biopsies decrease in b-adrenoceptors and an increase in Gia-profrom patients with heart failure and treated with metoprolol teins, and in the presence of unchanged Gsa or catalyst for six months, a reduction of pertussis toxin substrates has activities. Carvedilol treatment did not reverse the biobeen observed [39] . In spontaneously hypertensive rats, chemical changes despite its antiadrenergic effects in vivo. treatment with fosinopril reduced sympathetic activation An atypical guanine nucleotide-sensitive interaction of and reduced the elevated levels of Gia-proteins [40] .
carvedilol with b-adrenergic receptors could be responsible However, carvedilol had no effect on G-protein levels and, for these atypical effects. These findings support evidence consistently, did not restore guanine nucleotide-dependent for an effectiveness of carvedilol in the treatment of heart stimulation of adenylyl cyclase activity. Consistent with failure that is independent of b-adrenergic signal transducthe lack of upregulation of b-adrenergic receptors and tion. Identification of these mechanisms would provide Gia-proteins, neuropeptide Y concentrations were not insights into the mechanisms of heart failure and the affected. Taken together, carvedilol does not influence development of new therapeutic strategies for this maligb-adrenergic signal transduction, although it does produce nant condition. antiadrenergic effects in vivo.
From this and previous studies, one has to assume that carvedilol does not influence b-adrenergic signal transduc
